Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma by Tanzima Nuhat Sharna et al.
Droplet digital polymerase chain reaction
assay and peptide nucleic acid-locked nucleic
acid clamp method for RHOA mutation detection
in angioimmunoblastic T-cell lymphoma
著者 Tanzima Nuhat Sharna, Sakata-Yanagimoto
Mamiko, Komori Daisuke, Hattori Keiichiro,
Suehara Yasuhito, Fukumoto Kota, Fujisawa
Manabu, Kusakabe Manabu, Matsue Kosei,
Wakamatsu Hirotake, Shimadzu Mitsunobu, Chiba
Shigeru
journal or
publication title
Cancer science
volume 109
number 5
page range 1682-1689
year 2018-03
権利 (C) 2018 The Authors. Cancer Science published
by John Wiley & Sons Australia, Ltd on behalf
of Japanese Cancer Association.
This is an open access article under the terms
of the Creative Commons
Attribution-NonCommercial-NoDerivs License,
which permits use and distribution in any
medium, provided the original work is properly
cited, the use is non-commercial and no
modifications or adaptations are made.
URL http://hdl.handle.net/2241/00152980
doi: 10.1111/cas.13557
Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
OR I G I N A L A R T I C L E
Droplet digital polymerase chain reaction assay and peptide
nucleic acid-locked nucleic acid clamp method for RHOA
mutation detection in angioimmunoblastic T-cell lymphoma
Sharna Tanzima Nuhat1 | Mamiko Sakata-Yanagimoto2 | Daisuke Komori1 |
Keiichiro Hattori1 | Yasuhito Suehara1 | Kota Fukumoto1 | Manabu Fujisawa1 |
Manabu Kusakabe2 | Kosei Matsue3 | Hirotake Wakamatsu4 |
Mitsunobu Shimadzu4 | Shigeru Chiba2,5
1Department of Hematology, Graduate
School of Comprehensive Human Sciences,
University of Tsukuba, Tsukuba, Japan
2Department of Hematology, Faculty of
Medicine, University of Tsukuba, Tsukuba,
Japan
3Division of Hematology/Oncology,
Department of Internal Medicine, Kameda
Medical Center, Kamogawa, Japan
4LSI Medience Co., Tokyo, Japan
5Life Science Centre of Tsukuba Advanced
Research Alliance University of Tsukuba,
Tsukuba, Japan
Correspondence
Mamiko Sakata-Yanagimoto and Shigeru
Chiba, Department of Hematology, Faculty
of Medicine, University of Tsukuba, Tsukuba,
Japan.
Emails: sakatama-tky@umin.net;
schiba-tky@umin.net
Funding information
Ministry of Education, Culture, Sports, and
Science of Japan (16H02660), Practical
Research for Innovative Cancer Control from
Japan Agency for Medical Research and
Development, AMED, Kobayashi Foundation
for Cancer Research, Leukemia Research
Fund, and Takeda Science Foundation for
Cancer Research.
Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of nodal peripheral T-cell
lymphoma (PTCL). Somatic RHOA mutations, most frequently found at the hotspot
site c.50G > T, p.Gly17Val (G17V RHOA mutation) are a genetic hallmark of AITL.
Detection of the G17V RHOA mutations assists prompt and appropriate diagnosis
of AITL. However, an optimal detection method for the G17V RHOA mutation
remains to be elucidated. We compared the sensitivity and concordance of
next-generation sequencing (NGS), droplet digital PCR (ddPCR) and peptide nucleic
acid-locked nucleic acid (PNA-LNA) clamp method for detecting the G17V RHOA
mutation. G17V RHOA mutations were identified in 27 of 67 (40.3%) PTCL samples
using NGS. ddPCR and PNA-LNA clamp method both detected G17V mutations in
4 samples in addition to those detected with NGS (31 of 67, 46.3%). Additionally,
variant allele frequencies with ddPCR and those with NGS showed high concor-
dance (P < .001). Three other RHOA mutations involving the p.Gly17 position
(c.[49G > T;50G > T], p.Gly17Leu in PTCL198; c.[50G > T;51A > C], p.Gly17Val in
PTCL216; and c.50G > A, p.Gly17Glu in PTCL223) were detected using NGS. These
sequence changes could not appropriately be detected using the ddPCR assay and
the PNA-LNA clamp method although both indicated that the samples might have
mutations. In total, 34 out of 67 PTCL samples (50.7%) had RHOA mutations at the
p.Gly17 position. In conclusion, our results suggested that a combination of ddPCR/
PNA-LNA clamp methods and NGS are best method to assist the diagnosis of AITL
by detecting RHOA mutations at the p.Gly17 position.
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1 | INTRODUCTION
ngioimmunoblastic T-cell lymphoma (AITL) is a distinct subtype of nodal
peripheral T-cell lymphoma (PTCL).1 A large percentage of patients
(68%-94%) present with advanced-stage disease (stages III-IV) at diagno-
sis.2 High fever, skin rash, hepatosplenomegaly, pleural effusions, and
generalized lymphadenopathy are predominant clinical features of AITL.
Autoimmune-like manifestations including hemolytic anemia and poly-
clonal hypergammaglobulinemia are also frequently observed. AITL
tumor cells display features of follicular helper T (TFH) cells.
3 Recurrent
genetic abnormalities frequently found in AITL include mutations in
RHOA (50%-70%),4-6 TET2 (47%-83%),4,7,8 IDH2 (20%-45-
%),4,9 DNMT3A (20%-30%),4,7,10 and CD28 (9.4%-11.3%).11-13 The vast
majority of RHOA mutations found in AITL are c.50G > T, p.Gly17Val
(G17V RHOA mutations),4-6 although different RHOA mutations at the
p.Gly17 position (c.49_51del, p.Gly17del,4 c.[50G > T;51A > C],
p.Gly17Leu,14 and c.50G > A, p.Gly17Leu6) were reported. Peripheral
T-cell lymphoma, not otherwise specified (PTCL-NOS) is a T-cell lym-
phoma that cannot be categorized into any subtypes of PTCL (although
some PTCL-NOS cases show tumor cells with TFH-like features
4,8).1 In
2016, the revised WHO classification used an umbrella category for
nodal T-cell lymphomas with TFH phenotype that comprise AITL, follicu-
lar T-cell lymphoma (FTCL), and nodal PTCL with TFH phenotype.
1 The
G17V RHOA mutations, which are extremely rare in the other hemato-
logical cancers, are found in approximately 60% of cases of nodal PTCL
with TFH phenotype.
4,11 The frequent and specific distribution of G17V
RHOA mutations in AITL and nodal PTCL with TFH phenotype highlights
the diagnostic value of this mutation for these subtypes of PTCL.
In clinical practice, routine detection of G17V RHOA mutations is
challenging as a result of the low ratio of tumor cells in AITL tissues.
Additionally, insufficient quality of genomic DNA derived from biopsy
specimens hinders efficient and robust mutation testing. Hence, opti-
mized methods capable of overcoming these problems are needed for
detecting G17V RHOA mutations in the clinical setting. In the present
study, we carried out extensive analyses of G17V RHOA mutations
using droplet digital PCR (ddPCR), peptide nucleic acid-locked nucleic
acid (PNA-LNA) clamp method, and next-generation sequencing (NGS)
to clarify the concordance and sensitivity of these methods.
2 | MATERIALS AND METHODS
2.1 | Patients
Sixty-seven patients with PTCL (40 AITL and 27 PTCL-NOS) were
included into this retrospective study (Table S1). The study was
approved (approval numbers are H 24-74 and H 28-268) by the ethical
committee of University of Tsukuba Hospital.
2.2 | Sample collection and DNA extraction
Genomic DNAs were extracted from frozen samples using a nucle-
ospin tissue kit (Macherey-Nagel, D€uren, Germany) according to the
manufacturer’s instructions. Concentrations of the extracted DNAs
were measured using a Qubit 2.0 fluorometer (Thermo Fisher Scien-
tific, Waltham, MA, USA). The extracted DNAs were stored at
20°C until use.
2.3 | Primer design and amplicon preparation for
deep sequencing
Amplification reactions were carried out with 20 ng extracted genomic
DNA as the template in a 10-lL reaction volume with Kod-Plus-Neo PCR
reagent (TOYOBO, Osaka, Japan), and 300-nmol/L concentration of
forward (50-GCCCCATGGTTACCAAAGCA-30) and reverse primers
(50-ACATGGAAAATGGCATCAGTTGTT-30). The two-step cycling param-
eters used to amplify the PCR product were: 94°C for 2 minutes, 35
cycles at 98°C for 10 seconds, and at 68°C for 30 seconds. Amplicons
were visualized on a 1% agarose gel stained with ethidium bromide.
2.4 | Library preparation and amplicon-based deep
sequencing
Libraries were prepared from the PCR products using an IonPGM
fragment library preparation kit (Thermo Fisher Scientific) as previ-
ously described.15 Briefly, PCR amplicons were ligated to barcode
adapters and P1 adapters before amplification. The amplified libraries
were quantitated using quantitative PCR with the Ion Library Quan-
titation kit according to the manufacturer’s instructions (Thermo
Fisher Scientific). Libraries were then subjected to deep sequencing
on the Ion Torrent PGM platform according to the standard protocol
for 300 base-pair single-end reads (Thermo Fisher Scientific).
Sequencing data were analyzed using Variant Caller 5.0 (Thermo
Fisher Scientific). Results of RHOA mutation analysis of 50 PTCL
samples using NGS were previously described (Table S2).16
2.5 | ddPCR assay
The PCR primer/probe mix for the G17V RHOA mutation was pur-
chased from Bio-Rad (Hercules, CA, USA). The probe fluorophores
used for mutant and wild-type DNA were FAM and HEX, respec-
tively. A 20-lL reaction mixture containing 10 lL ddPCR supermix
for probe (no dUTP) 9 2 (Bio-Rad), 1 lL of 10 lmol/L primer/probe
mix, and 40 ng DNA template was mixed with 70 lL droplet genera-
tion oil through microfluidics in the Droplet Generator (Bio-Rad). Fol-
lowing droplet generation, the water-in-oil droplets were transferred
to a standard 96-well PCR plate, which was heat sealed with a foil
plate seal (Bio-Rad) and placed on a Bio-Rad thermocycler for PCR
amplification using the following protocol: 10 minutes at 95°C, fol-
lowed by 40 cycles of 30 seconds at 94°C, and 60 seconds at
53.1°C, followed by a 10-minute hold at 98°C. Upon completion of
the PCR, the plate was transferred to a Droplet Reader (Bio-Rad).
The data were initially analyzed using QuantaSoft software (Bio-
Rad). The fluorescence threshold was set at 5000 for FAM and
2000 for HEX. Wells with less than 3 positive oil droplets were con-
sidered as negative, except for wells with 2 positive droplets show-
ing reproducible results, which were considered as positive.
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2.6 | PNA-LNA PCR clamp method
For PNA-LNA PCR clamp, PCR primers (forward and reverse primers
200 nmol/L each), fluorogenic probes (total probe and LNA
100 nmol/L each), and a PNA clamp primer (50 nmol/L) were added
to the Premix Ex taq (Probe qPCR) Master Mix (Takara, Shiga,
Japan). Total probe (fluorescent dye Cy5) targeted normal sequences
and LNA probe (fluorescent dye FAM) targeted the sequences with
the G17V mutation. The primer and probe sequences used to detect
the G17V RHOA mutations are listed in Table S3. Quantitative PCR
was then carried out with a 30 seconds hold at 95°C followed by 45
cycles at 95°C for 3 seconds, and 62°C for 30 seconds.
2.7 | Statistical analysis
Statistical analysis was conducted using SPSS software (IBM Japan,
Tokyo, Japan). The correlation between variant allele frequencies
(VAF) from ddPCR assay and those from NGS was analyzed using
Spearman’s correlation coefficient. P-value <.05 was considered sta-
tistically significant.
3 | RESULTS
3.1 | Mutation detection sensitivity of ddPCR assay
At first, we established the lower limits of detection (LOD) and
quantification (LOQ) for ddPCR assay. For this, serial dilution sam-
ples were prepared to make the VAF of the G17V mutation at 13%,
3.25%, 0.81%, 0.20%, 0.05%, 0.01%, and 0.0025%. WT genomic
DNA and distilled water (DW) were used as negative control and no
template control, respectively (Figure S1A). Analysis of the result
using ddPCR assay showed highly concordant VAFs with input DNA
templates (R2 = .9996) (Figure S1A).
After being converted to log-log scale, data showed precision
and linearity down to a dilution of 0.05%; which corresponded to a
fractional abundance (proportion of the mutated DNA; QuantaSoft)
of 0.06% (coefficient of determination [R2] was .9996). The positive
control diluted to 0.01% was also judged as positive using ddPCR
assay, whereas the fractional abundance was 0.02% (Figure S1A).
Mutant alleles at a frequency of <0.01% could not be detected and,
thus, <0.01% was considered as negative.
For these reasons, LOQ of ddPCR assay was defined as 0.05%
with a fractional abundance of 0.06%. Further experiments showed
that LOD could be lowered to 0.01% with a fractional abundance of
0.02%.
3.2 | Mutation detection sensitivity of the PNA-
LNA clamp method
Next, we investigated the detection limit of the PNA-LNA PCR
clamp method for the G17V RHOA mutation. The mutant DNA was
mixed with WT DNA to generate different dilution samples at 1%,
0.1%, 0.01%, and 0.001% (Figure S1B). The PNA-LNA PCR clamp
method was able to detect the G17V RHOA sequence at dilutions
down to 0.01% but not 0.001% (Figure S1B). Because of the
limitation of this method, we could not measure the quantity of the
mutations.
3.3 | Comparison of mutations detected by
different methods
Using the data from the 67 PTCL samples we compared the concor-
dance rates of the above-mentioned 3 methods (Table S2; Figure 1).
c.50G > T, p.Gly17Val RHOA mutations were detected in 27 of the
67 PTCL samples (40.3%) (AITL 20/40 [50.0%], PTCL-NOS 7/27
[25.9%]) with NGS (Figure 1A,C; Table S2). ddPCR assay and PNA-
LNA clamp method could detect low mutant alleles in 4 cases, which
were not detected with NGS (PTCL171, PTCL186, PTCL209, and
PTCL259; Figure 2). The mutation ratio according to ddPCR assay
was 0.13%, 0.03%, 0.05%, and 0.21% for PTCL171, PTCL186,
PTCL209, and PTCL259, respectively. Amplification curves of these
samples produced using the PNA-LNA clamp method were also
clearly distinguishable from the WT (Figure 2B). In total, 31 of 67
samples (46.3%) (AITL 23/40 [57.5%], PTCL-NOS 8/27 [29.6%])
were positive for the c.50G > T, p.Gly17Val RHOA mutations with
both the ddPCR assay and the PNA-LNA method (Figure 1A,C;
Table S2), indicating that the results of these two methods were
100% concordant for detecting positive and negative samples (Fig-
ure 1A,C; Table S2). Furthermore, the data showed that the ddPCR
assay and the PNA-LNA method have higher sensitivity than NGS
for detecting G17V RHOA mutations in samples.
According to the quantitative results of the ddPCR assay, muta-
tion ratio in the ddPCR assay and VAF in NGS were statistically cor-
related (Spearman’s correlation coefficient 0.868, P-value <.001)
(Figure 3). Inter-method discrepancies more than double were found
in 2 samples (PTCL252 with a VAF of 19.8% in NGS and a mutation
ratio of 4.6% in ddPCR assay; PTCL245 with a VAF of 76.4% in
NGS and a mutation ratio of 14.28% in ddPCR assay).
3.4 | Analysis of the other RHOA mutations at the
p.Gly17 position using the ddPCR assay and the
PNA-LNA clamp method
Three other RHOA mutations at the p.Gly17 position were detected
using NGS: c.[49G > T;50G > T], p.Gly17Leu in PTCL198;
c.[50G > T;51A > C], p.Gly17Val in PTCL216; and c.50G > A,
p.Gly17Glu in PTCL223 instead of the c.50G > T, p.Gly17Val RHOA
mutations (Fujisawa et al.16 and Figure 4). As described above, we
observed that the fluorescence amplitude of FAM-positive droplets
in a reaction was more than 5000 for all c.50G > T mutation-posi-
tive samples with the ddPCR assay. However, those samples having
the other RHOA mutations at the p.Gly17 position (PTCL198,
PTCL216, and PTCL223) showed clusters of droplets lower than
5000, which were clearly separable from the WT droplets (Fig-
ure 4A). Furthermore, analysis of each of these samples using the
PNA-LNA clamp method showed different crossing point (Cp) values
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of the amplification curves from those of either WT or the G17V
RHOA mutations (Figure 4C). Experiments using the c.50G > T,
p.Gly17Val probe did not show amplification in these samples, simi-
lar to those without the p.Gly17 RHOA mutations (Figure 4C). Total
probe detected amplification, which was not appropriately clamped
by addition of PNA (Figure 4D). The cutoff Cp value of WT with
total probe was > 34. The Cp values in PTCL198, PTCL216, and
PTCL223 with total probe were 28.63, 27.09, and 31.18, respec-
tively, indicating that they are <34 in PTCL samples.
Further experiments with Sanger sequencing confirmed other
RHOA mutations (c.[49G > T;50G > T], p.Gly17Leu in PTCL198; and
c.[50G > T;51A > C], p.Gly17Val in PTCL216; and c.50G > A,
p.Gly17Glu in PTCL223, respectively) at the p.Gly17 position (Fig-
ure 4B) which were previously detected by NGS. These data indicate
that the ddPCR assay and the PNA-LNA clamp method could predict
mutations around the p.Gly17 position, although neither method
could determine the exact mutation type.
In total, RHOA mutations at the p.Gly17 position were found in
34 out of 67 PTCL samples (50.7%) (AITL 26/40 [65.0%], PTCL-NOS
8/27 [29.6%]) by either NGS, ddPCR assay or the PNA-LNA clamp
method (Table S2; Figure 1B,D). We found that the results of the
ddPCR and PNA-LNA clamp methods were concordant (j = 1 and
P < .0001). In addition, the kappa and P-values were .82 and <.0001,
respectively, for both ddPCR and NGS, and PNA-LNA clamp method
and NGS. We considered those samples as true positive which were
positive by at least 2 methods (among ddPCR, PNA-LNA clamp
method, NGS, and Sanger sequencing). Moreover, those samples that
were negative by all 4 above-mentioned methods were considered
as true negative. There were no samples in which RHOA mutations
were detected by 1 method only. As a result, the sensitivity of
F IGURE 1 Study profile. A,B, Frequencies of A, RHOA c.50G > T, p.Gly17Val mutations, and B, total RHOA mutations detected by droplet
digital PCR (ddPCR) assay and peptide nucleic acid-locked nucleic acid (PNA-LNA) method, and next generation sequencing (NGS); and either
ddPCR assay, PNA-LNA clamp method or NGS. AITL, angioimmunoblastic T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not
otherwise specified. C,D, Venn diagrams of the frequencies of C, RHOA c.50G > T, p.Gly17Val mutations, and D, total RHOA mutations
detected by ddPCR assay, PNA-LNA method and NGS
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ddPCR and PNA-LNA clamp method for detection of c.50G > T,
p.Gly17Val mutation was 100% (31/31) with 100% (36/36) speci-
ficity, whereas NGS had 87% (27/31) sensitivity with 100% (36/36)
specificity. In contrast, for detection of all RHOA mutations at posi-
tion 17, ddPCR and the PNA-LNA clamp method had 91% (31/34)
sensitivity with 100% (33/33) specificity, and NGS had 88% (30/34)
sensitivity with 100% (33/33) specificity.
4 | DISCUSSION
RHOA mutation detection has been increasingly focused for diagno-
sis of AITL and PTCL with TFH phenotype.
14,17 Herein, we clarified
that the ddPCR assay and the PNA-LNA clamp method could detect
low allele mutations with extremely high sensitivity. In addition,
mutation quantification by ddPCR assay showed results concordant
with those by NGS. Although we found some discordances in VAF
of 2 samples (PTCL245 and PTCL252), insufficient DNA quantity
and quality may account for the discordant results, which is some-
times experienced in clinical settings. In contrast, the other RHOA
mutations at the p.Gly17 position, which were detected by NGS
could not be appropriately detected by either ddPCR assay or the
PNA-LNA clamp method. As a result, combination of these methods
increased the detection rate of RHOA mutations at the p.Gly17 posi-
tion. We recently reported essential downstream signaling of G17V
RHOA mutations in PTCL: the G17V mutant RHOA hyper-activated
the T-cell receptor (TCR) signaling pathway through specific binding
to VAV1 protein, an essential component in TCR signaling.16 The
other RHOA mutants at the p.Gly17 position presumably have a sim-
ilar function, although it has not been examined.
There are several well-established methods to detect gene muta-
tions in cancers. Among them, NGS has attracted attention over the
past few years as a possible method for mutational analysis.
Although the sensitivity of NGS is superior to that of direct
F IGURE 2 Detection of low-frequency mutations of G17V RHOA using droplet digital PCR (ddPCR) assay and peptide nucleic acid-locked
nucleic acid (PNA-LNA) clamp method with G17V probe. A, 2D images of ddPCR analysis of samples PTCL171, PTCL186, PTCL209, and PTCL259.
Pink color lines indicate FAM (horizontal) and HEX (vertical) threshold. B, Amplification curves produced by PNA-LNA clamp method with G17V
probe for samples PTCL171, PTCL186, PTCL209, and PTCL259. PTCL, peripheral T-cell lymphoma. NC, negative control; PC, positive control
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sequencing, our findings suggest that NGS cannot detect low allele
mutations.
Recently, the ddPCR assay has been widely used to detect
genetic and epigenetic alterations.18-21 ddPCR can detect very
rare sequences with high precision and sensitivity by partitioning
individual target molecules within distinct compartments and,
therefore, reduces the limitations of conventional methods such
as classic real-time quantitative PCR (qPCR) or the amplification
refractory mutation system qPCR (ARMS qPCR).22-24 However,
the PNA-LNA clamp method is a molecular probe-based PCR
method; its unique design and allele-specific approach allow
exceptionally high specificity and sensitivity.25,26 The NGS plat-
form is more convenient for massive parallel sequencing of
known and unknown mutations in multiple genes.27 In contrast,
to detect a known target mutation within a single gene, both the
F IGURE 3 Comparison of mutational load quantified using
droplet digital PCR (ddPCR) assay and next generation sequencing
(NGS). Direct comparison of mutation ratio by ddPCR assay and
variant allele frequencies (VAF) using NGS
F IGURE 4 Samples having RHOA
mutations at the p.Gly17 position other
than c.50G > T, which could not be
detected with droplet digital PCR (ddPCR)
assay. A, 2D image of ddPCR assay of
samples PTCL198, PTCL216, PTCL223,
and wild type (WT). Pink color lines
indicate FAM (horizontal) and HEX
(vertical) threshold. B, Sanger sequencing
result of samples PTCL198, PTCL216,
PTCL223, and WT. C, Amplification curve
produced by peptide nucleic acid-locked
nucleic acid (PNA-LNA) clamp method with
G17V probe for samples PTCL198,
PTCL216, PTCL223, and WT. D,
Amplification curve produced by PNA-LNA
clamp method with total probe for samples
PTCL198, PTCL216, PTCL223, and WT
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ddPCR assay and the PNA-LNA clamp method have an economi-
cal advantage over NGS. The latter is not a quantitative method,
because it relies on the threshold and quantification cycle (Cq)
value for interpretation of the result, whereas ddPCR is indepen-
dent of the Cq value and requires a relatively small amount of
initial DNA.23,24 However, the PNA-LNA clamp method is less
expensive and clinically more accessible for mutation screening
compared to ddPCR or NGS.28
To date, quantitative allele-specific PCR and other methods are
being tried to detect the G17V RHOA mutation.17 Several hotspot
mutations such as V617F JAK2 in myeloproliferative neoplasms,29
V600E BRAF in hairy cell leukemia,30 L265P MYD88 in Waldenstr€om
macroglobulinemia,31 and D661Y/Y640F/S614R STAT3 in large
granular lymphocytic leukemia32 are being used for diagnostic pur-
poses by means of NGS,33 ddPCR,34 ARMS-PCR,35 allele-specific
PCR,36 high resolution melting,37 qPCR,38 and so on. The present
study is the first report to evaluate the use of the ddPCR assay and
the PNA-LNA clamp method for detection of low abundance RHOA
G17V mutation.
In conclusion, our findings shed light on the potential of these
techniques for the molecular diagnosis of AITL.
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